Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 14OTHER 11NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Osteosarcoma 1Neuroblastoma 1Multiple Myeloma 1Melanoma 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × AP 1903 reagent × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

NCT03958656 2021-09-09

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
13 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡